| 0.2639 0.042 (18.87%) | 08-19 12:29 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.31  |
1-year : | 0.37 |
| Resists | First : | 0.27 |
Second : | 0.31 |
| Pivot price | 0.2 |
|||
| Supports | First : | 0.21 |
Second : | 0.17 |
| MAs | MA(5) : | 0.22 |
MA(20) : | 0.2 |
| MA(100) : | 0.31  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 64.7 |
D(3) : | 60.9 |
| RSI | RSI(14): 64.9 |
|||
| 52-week | High : | 9.18 | Low : | 0.17 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CURX ] has closed above the upper band by 18.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 31.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.23 - 0.23 | 0.23 - 0.23 |
| Low: | 0.2 - 0.2 | 0.2 - 0.21 |
| Close: | 0.22 - 0.22 | 0.22 - 0.22 |
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Mon, 17 Aug 2026
Curanex Announces Reverse Stock Split to Maintain Nasdaq Listing - TipRanks
Mon, 17 Aug 2026
Curanex Pharmaceuticals Inc Common Stock (NASDAQ: CURX) Stock Price, News & Analysis - Kalkine
Fri, 17 Apr 2026
Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX - Business Wire
Mon, 06 Apr 2026
Curanex Pharmaceuticals Highlights Patient Case Supporting Phyto-N's Potential in Cancer Cachexia Treatment - Quiver Quantitative
Thu, 18 Sep 2025
CURX Pharmaceuticals: A New Dawn or a Passing Surge? - StocksToTrade
Wed, 27 Aug 2025
Curanex Pharmaceuticals (CURX) Stock Price, News & Analysis - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 67.8 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 137 (K) |
| Shares Short P.Month | 115 (K) |
| EPS | -0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.1 % |
| Return on Equity (ttm) | -85.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -12.73 |
| PEG Ratio | 0 |
| Price to Book value | 25.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|